Advancing Brain Organoids from Research Models to Scalable Platforms

The item is a Genetic Engineering & Biotechnology News (GEN) webinar post titled 'Advancing Brain Organoids from Research Models to Scalable Platforms.' The provided excerpt centers on a webinar featuring Joseph Shultz, VP of technical development and manufacturing at Ottimo Pharma, and Imroz Ghangas, VP of commercial sales at Asimov.

The speakers discuss strategies for achieving high-performing clonal titers and for advancing a dual-paratopic cancer immunotherapy from sequence to dosed patient in under a year. The excerpt does not include further specifics on the brain organoid scalability topic named in the title.